BioCryst Pharmaceuticals (BCRX) Financials

BioCryst Pharmaceuticals Inc (BCRX) is a biotechnology company focused on the discovery, development, and commercialization of novel small molecule drugs for the treatment of rare diseases. The company's primary focus is on oral and intravenous (IV) formulations of various drugs that target specific enzymes involved in disease processes. The company's key products include berotralstat and galidesivir, which are being developed for the treatment of hereditary angioedema and viral infections, respectively.

In terms of financials, BioCryst Pharmaceuticals Inc (BCRX) has reported positive growth in recent years. The company's total revenue has increased from $53.7 million in 2016 to $215.2 million in 2020, representing a compound annual growth rate (CAGR) of 41.9%. Similarly, the company's gross profit has also shown impressive growth, increasing from $24.2 million in 2016 to $198.3 million in 2020, with a CAGR of 78.1%.

However, BioCryst Pharmaceuticals Inc (BCRX) has also incurred significant expenses related to research and development (R&D) activities. The company's R&D expenses have increased from $77.2 million in 2016 to $176.8 million in 2020, reflecting its commitment to advancing its pipeline of drug candidates. As a result, the company has reported a net loss from stockholders of $126.8 million in 2020.

Despite the net loss, BioCryst Pharmaceuticals Inc (BCRX) has a strong balance sheet. The company's total assets have increased from $344 million in 2016 to $703.6 million in 2020, primarily driven by an increase in cash and cash equivalents. The company's cash equivalents have grown from $154.4 million in 2016 to $440.9 million in 2020.

As of the end of 2020, BioCryst Pharmaceuticals Inc (BCRX) had a net debt of $32.3 million. The company's stockholders' equity stood at $541.3 million, representing a significant portion of its total liabilities, which amounted to $121.2 million. BioCryst Pharmaceuticals Inc (BCRX) has been able to generate positive operating cash flow, with $100.9 million in 2020. The company's free cash flow, which represents the cash remaining after all operating expenses and capital expenditures have been paid, was $77.8 million in 2020.

In summary, BioCryst Pharmaceuticals Inc (BCRX) has shown strong financial performance in recent years, with significant growth in total revenue and gross profit. The company's focus on developing novel drugs for the treatment of rare diseases has resulted in substantial R&D expenses and a net loss, but its solid balance sheet and positive cash flow demonstrate its ability to sustain its operations and invest in future growth.